Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7006 to 7020 of 7675 results

  1. Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing elective surgery [ID1149]

    Discontinued [GID-TA10297]

    Technology appraisal guidance
    Discontinued

  2. Atezolizumab for untreated advanced renal cell carcinoma [ID1365]

    Discontinued [GID-TA10338]

    Technology appraisal guidance
    Discontinued

  3. Arimoclomol for treating Niemann-Pick disease Type C [ID1312]

    In development [GID-HST10037] Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  4. Lasmiditan for treating acute migraine [ID3759]

    Discontinued [GID-TA10807]

    Technology appraisal guidance
    Discontinued

  5. Durvalumab with tremelimumab for untreated EGFR- and ALK-negative locally advanced and metastatic non-small-cell lung cancer [ID1538]

    Discontinued [GID-TA10422]

    Technology appraisal guidance
    Discontinued

  6. Nivolumab with docetaxel for treating hormone-relapsed advanced prostate cancer after 1 or 2 hormonal therapies [ID4048]

    In development [GID-TA10929] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Durvalumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3762]

    Discontinued [GID-TA10633]

    Technology appraisal guidance
    Discontinued

  8. Pembrolizumab with docetaxel for treating hormone-relapsed metastatic prostate cancer untreated with chemotherapy [ID3801]

    Discontinued [GID-TA10668]

    Technology appraisal guidance
    Discontinued

  9. Avatrombopag for treating chemotherapy-induced thrombocytopenia in non-haematological cancers [ID3837]

    Discontinued [GID-TA10737]

    Technology appraisal guidance
    Discontinued

  10. Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor [ID6213]

    In development [GID-TA11204] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Subcutaneous atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after platinum-based chemotherapy TS ID 11801

    Discontinued [GID-TA11180]

    Technology appraisal guidance
    Discontinued

  12. Emapalumab for treating primary haemophagocytic lymphohistiocytosis (ID1438)

    Discontinued [GID-TA10527]

    Technology appraisal guidance
    Discontinued

  13. Atezolizumab with chemotherapy for neoadjuvant treatment of resectable early or locally advanced invasive triple-negative breast cancer [ID1574]

    Discontinued [GID-TA10531]

    Technology appraisal guidance
    Discontinued

  14. Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]

    In development [GID-TA10597] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Maribavir for cytomegalovirus infection after haematopoietic stem cell transplant [ID5075]

    In development [GID-TA10958] Expected publication date: TBC

    Technology appraisal guidance
    In development